Company: IXHL
Filing Date: 2025-04-16
Form Type: S-1/A
Source: 0001213900-25-032577
Chunk: 10

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-16
Form: S-1/A
Chunk 10
---
, dividends, reclassifications and similar adjustments.

In addition, if
we grant, issue or sell any options, convertible securities, or rights to purchase stock, warrants, securities or other property on
a pro rata basis to the record holders of our common stock (such rights, the “Purchase Rights”), then each holder of a
Warrant will be entitled to participate in this offering of Purchase Rights as if the holder of a Warrant were a
holder of our common stock. The amount of Purchase Rights that a holder of a Warrant could acquire would be the amount of
Purchase Rights the holder could have acquired if the holder of a Warrant had held the number of shares of common stock
acquirable upon complete exercise of their Warrant immediately before the date on which a record date is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of our common
stock is determined for the grant, issue or sale of such Purchase Rights. The number of shares issuable to Series A Warrant holders will be without regard to any 4.99% or 9.99% beneficial ownership limitation
and the number issuable to the Pre-Funded warrant holders in excess of these blockers will be held in abeyance until such time as the
issuance would be in compliance with these blocker provisions.

<div align='center'>1</div>

The exercise price of the
Series A Warrants will be reduced (but in no event increased) to the greater of (I) the Floor Price (as described below) and (II) the
lowest daily dollar-volume-weighted-average-price during the period beginning two full trading days prior to the Release Date and ending
on the 10th trading day after the Release Date (as described below). Upon any such resulting adjustment of the exercise price in the Series
A Warrants, the number of Series A Warrant Shares issuable under the Series A Warrants will be increased such that the aggregate exercise
price of a Series A Warrants (adjusted for any exercises by a holder prior to this adjustment) will remain unchanged following such adjustment.
As a result, the aggregate number of shares of Common Stock underlying all of the Series A Warrants, may increase from 11,574,090 to up
to 115,740,900, assuming full adjustment of the exercise price to the Floor Price and before giving effect to the zero exercise price
provision